スクリーンショット 2022-03-08 午後4.04.51.png

Our Products


ACESOVITA™ is our initial product offering for Feline/Canine use. “Aceso” from the Greek, meaning “ healing” and “vita” from Latin, meaning “life”. ACESOVITA™ is a sterile, single-use device that is designed to treat various forms of solid tumor cancer and infectious disease in animals. The ACESOVITA™ device contains a 3-step process that is based on the Hetastarch method of processing cells which are infused into the animal.


ACESOVITA™ Renu is to activate immune cells to rejuvenate dogs. This is a direct-injection application.  Dogs treated with ACESOVITA™ Renu have shown signs of “puppyitis” with improved quality of life and activity.  Dogs will be monitored closely for activity and potential side-effects. The dose-level used in these treatments have been evaluated in normal dogs and no adverse effects have been observed.


PROLOVITA™ is intended for the treatment of various forms of cancer and infectious disease in animals. “Prolo” is short for “prolong” and “vita” from Latin, meaning “life”. PROLOVITA™ is a multi-step process that is based on the Ficoll method of processing cells, requiring a laminar flow hood, centrifugation, and multiple cell washes.  Resulting in a purified cell pellet which is reconstituted and infused into the animal.


EUNOVITA™ is intended for the stabilization of cells so that they can be cryo-preserved for Feline/Canine use. “Euno” is short for the Greek goddess of stability “Eunumia”. Eunovita™ follows the identical process as PROLOVITA™, however, the purified cell pellet can be reconstituted with a cryo-medium and frozen from -80ºC to -196ºC. The cells can be captured at a young age and used at a later time in the animal’s life when needed to fight cancer, infection, or aging.


EQUIVITA™ is based on the same 3-step process as ACESOVITA™, using the Hetastarch method of processing cells for use in horses. “Equi” being short for “equine”, the product can be processed in the field or in a barn or ranch setting and can be administered to the horse immediately.  This will require a clinical study and submission and approval for commercialization.